Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 2, 2011, Pages 85-92

  Machado, Marcel Cerqueira Cesar ^a   Bellodi Privato, Marta ^a   Kubrusly, Márcia Saldanha ^a   Molan, Nilza Aparecida Trindade ^a   Tortelli Jr , Tharcisio ^a   De Oliveira, Erika Rodrigues ^a   D'Albuquerque, Luiz Augusto Carneiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Hepatocellular carcinoma; Notch 1 gene; Valproic acid

Indexed keywords

CASPASE 3; DNA; MESSENGER RNA; NOTCH1 RECEPTOR; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DEGRADATION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959242392     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
2. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5: 409-418, 2004. (Pubitemid 38878044)
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
4. Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett 286: 114-120, 2009.
5. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse AW, Galle PR. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15: 227-230, 2006.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 348: 2042-2054, 2003.
7. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
8. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H Moriwaki H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 285: 210-217, 2009.
9. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222, 2008.
10. Stockhausen MT, Sjölund J, Manetopoulos C, Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 92: 751-759, 2005. (Pubitemid 40460614)
11. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M Chen H. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12: 942-951, 2007. (Pubitemid 47359136)
12. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002. (Pubitemid 34146430)
13. Yamashita Y, Shimada M, Harimoto N Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103: 572-576, 2003. (Pubitemid 36091459)
14. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217, 2005. (Pubitemid 40143467)
15. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther 1: 466-476, 2002.
16. Maillard I, Pear WS. Notch and cancer: best to avoid the ups and downs. Cancer Cell 3: 203-205, 2003. (Pubitemid 37443875)
17. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H Guo Z, Cheng T, Cao X. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63: 8323-8329, 2003.
18. Ning L, Wentworth L, Chen H, Weber SM. Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res 1: 358-366, 2009.
19. Wang M, Xue L, Cao Q, Lin Y, Ding Y, Yang P, Che L. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 56: 533-541, 2009.
20. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 244: 265-273, 2006. (Pubitemid 44305542)
21. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3: 593-603, 2002. (Pubitemid 35174678)
22. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574, 2007. (Pubitemid 46295136)
23. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
24. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002. (Pubitemid 37361445)
25. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003.
26. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekström TJ. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol. 22: 579-588, 2003.
27. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003. (Pubitemid 36951018)
28. Nijjar SS, Crosby HA, Wallace L, Hubscher SG, Strain AJ. Notch receptor expression in adult human liver: a possible role in bile duct formation and hepatic neovascularization. Hepatology 34: 1184-1192, 2001. (Pubitemid 33096591)
29. Nijjar SS, Wallace L, Crosby HA, Hubscher SG, Strain AJ. Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol 160: 1695-1703, 2002. (Pubitemid 34525649)